Compounds and methods for treating sepsis
Patent Information
- Application Number
- PCT/US2023/079119
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-09
- Filing Date
- 2023-11-08
- Publication Date
- 2024-12-26
AI Technical Summary
Sepsis treatment is hindered by dysregulated lipid metabolism, leading to organ failure and high mortality rates, with existing studies indicating a link between HDL-C levels and sepsis outcomes but requiring further understanding of genetic underpinnings and targeted pathways.
Inhibition of the 7-Dehydrocholesterol Reductase (DHCR7) enzyme, either through chemical inhibitors or gene expression inhibitors like RNA interference, to reduce the severity and progression of sepsis by administering inhibitors such as AY9944, ziprasidone, or tamoxifen, which can be delivered via various routes including intravenous or subcutaneous.
The inhibition of DHCR7 reduces early death in sepsis models and shows potential in treating sepsis by ameliorating symptoms, reducing organ failure, and improving survival rates, as demonstrated in zebrafish and mouse models.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
Compounds and Methods for Treating Sepsis CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 382,979, filed November 9, 2022, which is incorporated herein by reference. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention was made with government support under grant numbers R01 GM133815, R35 HL150784, K12 HL133304, awarded by the National Institutes of Health. The government has certain rights in the invention. BACKGROUND
[0003] Sepsis is a dysregulated response to infection and is the costliest reason for hospital admission world-wide (Singer M et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA.2016 Feb 23;315(8):801-10). It occurs when a systemic infection results in a dysregulated immune response that leads to organ failure and potentially death. Survivors of sepsis are frequently left with reduced quality of life physical function, and long-term survival. Our group has defined and described clinically relevant outcomes that include early death (death within the first 14 days of sepsis), chronic critical illness (CCI, ICU stay > 14 days with organ failure), and rapid recovery (neither early death nor CCI). CCI patients frequently develop the persistent inflammation immunosuppression and catabolism syndrome (PICS), characterized by impaired physical function and one-year mortality rates over 40% (Mira JC et al.2017 Feb;45(2):253-262).
[0004] We and others have described the protective role of lipids and lipoproteins in sepsis (Guirgis FW et al. HDL inflammatory index correlates with and predicts severity of organ failure in patients with sepsis and septic shock. PLoS One.2018 Sep 14;13(9):e0203813; Guirgis FW et al. HDL inflammatory index correlates with and predicts severity of organ failure in patients with sepsis and septic shock. PLoS One.2018 Sep 14;13(9):e0203813; Morin EE et al. HDL in sepsis - risk factor and therapeutic approach. Front Pharmacol. 2015 Oct 23;6:244). High density lipoprotein (HDL) has antioxidant and anti-inflammatory proteins (paraoxonase-1 and apolipoprotein A-I) that protect against lipid oxidation, prevent inflammatory cell activation and chemotaxis, bind and clear bacterial toxins, and downregulate inflammatory pathways. Similarly, low density lipoprotein (LDL) may play a role in bacterial endotoxin clearance via the LDL receptor, particularly in gram negative sepsis, with proproteinconvertase subtilisin / kexin type 9 (PCSK9) playing an important regulatory role (Walley KR. Role of lipoproteins and proprotein convertase subtilisin / kexin type 9 in endotoxin clearance in sepsis. Curr Opin Crit Care. 2016 Oct;22(5):464-9; Walley KR et al. Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis. Crit Care Med. 2019 Mar;47(3):463-466; Walley KR et al. The Central Role of Proprotein Convertase Subtilisin / Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance. Am J Respir Crit Care Med.2015 Dec 1;192(11):1275-86). However, dysregulated lipid metabolism occurs in sepsis leading to HDL’s conversion to dysfunctional and pro- inflammatory HDL (Dys-HDL) that may play a role in organ failure progression, and the pathogenesis of CCI, and PICS (Guirgis FW et al. HDL inflammatory index correlates with and predicts severity of organ failure in patients with sepsis and septic shock. PLoS One.2018 Sep 14;13(9):e0203813 and Barker G et al. Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights into Chronic Critical Illness. J Clin Med. 2021 Apr 14;10(8):1693).
[0005] Recent studies have shed some light on the genetic underpinnings of lipid metabolism in sepsis. A UK Biobank study identified an important link between genetically determined HDL-C levels and decreased risk of hospitalizations for infectious disease, lower odds of outpatient antibiotic usage, and reduced risk of mortality from sepsis (Trinder M et al. Causal Inference for Genetically Determined Levels of High-Density Lipoprotein Cholesterol and Risk of Infectious Disease. Arterioscler Thromb Vasc Biol.2020;40(1):267-278). LDL-C and triglycerides levels did not confer the same risk reduction. However, the UK Biobank population were of homogenous ancestry. Another study identified that a rare missense variant in the cholesteryl ester transfer protein (CETP) gene (lowers HDL-C levels) was linked with reductions in HDL-C during sepsis (Trinder M et al. Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. Am J Respir Crit Care Med. 2019;199(7):854-862). Carriers of this risk allele had more severe organ failure and reduced 28-day survival. Although encouraging, further genetic studies of diverse cohorts are needed to understand the role of dysregulated lipid and lipoprotein metabolism in sepsis and how to target these pathways to improve outcomes in sepsis patients. SUMMARY
[0006] We have identified a gene, 7-Dehydrocholesterol Reductase (DHCR7), that is significantly upregulated in both chronic critical illness (CCI) and early death cohorts of sepsis patients compared to rapid recovery patients. Inhibition of DHCR7, either by inhibitingexpression of the gene or inhibiting activity of the encoded protein, reduces early death in a sepsis model system.
[0007] Described are methods for treating sepsis or systemic inflammatory response syndrome (SIRS) in a subject, comprising administering to the subject an inhibitor of 7- dehydrocholesterol reductase (Dhcr7).
[0008] In some embodiments, an inhibitor of DHCR7 can be an inhibitor of the encoded protein (Dhcr7) (i.e., a Dhcr7 inhibitor). In some embodiments the Dhcr7 inhibitor comprises a chemical inhibitor. The chemical inhibitor can be, but is not limited to, an atypical antipsychotic, a 5-HT2A receptor antagonist, a dopamine receptor agonist, a selective serotonin reuptake inhibitor (SSRI), a 5-HT1Areceptor agonist, and a β-2 adrenergic receptor agonist. In some embodiments, the inhibitor is selected from the group consisting of: AY9944, ziprasidone, ketanserin, pergolide, vilazodone, brexpiprazole, indacaterol, and tamoxifen.
[0009] The inhibitor can be administered to a subject by any suitable route appropriate for the inhibitor. In some embodiments, the inhibitor is administered orally, sublingually, buccally, intravenously, intramuscularly, intrathecally, subcutaneously, cutaneously, transdermally, nasally, or by inhalation.
[0010] In some embodiments, an inhibitor of DHCR7 can inhibit expression of the DHCR7 gene (i.e., a DCHR7 inhibitor). An DHCR7 inhibitor can be, but is not limited to, a DHCR7 RNA interference (RNAi) polynucleotide or a DHCR7 antisense oligonucleotide (ASO). An DHCR7 inhibitor can be administered to a subject by any suitable route appropriate for the DHCR7 inhibitor. In some embodiments, the DHCR7 inhibitor is administered via a lipid nanoparticle or a viral vector. The vial vector can be, but is not limited to: an adeno- associated virus (AAV) vector or lentivirus vector.
[0011] An inhibitor of DHCR7 can be administered to a subject that is suffering from sepsis or SIRS, diagnosed with sepsis or SIRS, suspected of suffering from sepsis or SIRS, or at risk of developing sepsis or SIRS.
[0012] An inhibitor of DHCR7 can be administered to a subject suffering from sepsis or at risk of developing sepsis to treat sepsis, to treat one or more symptoms associated with sepsis, to reduce the risk of developing one or more symptoms associated with sepsis, to prevent one or more symptoms associated with sepsis, or to decrease the risk of developing sepsis. The one or more symptoms associated with sepsis include, but are not limited to, organ failure, tissue damage, chronic critical illness (CCI), and early death.
[0013] An inhibitor of DHCR7 can be administered to a subject suffering from sepsis to ameliorate one or more symptoms associated with sepsis, to reduce the severity of the sepsis,and / or to prevent the progression of sepsis to chronic critical illness (CCI) or early death, or to improve outcome. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] FIG.1A. Depiction of workflow for RNA-seq data analysis.
[0015] FIG.1B-C. Tables representing significantly differentially expressed genes for the (B) derivation and validation cohorts and (C) by 90-day mortality.
[0016] FIG. 2A-B. Heatmaps illustrating differentially expressed genes for (A) derivation and (B) validation cohorts. First six genes (from top) in A are MSMO1, DHCR7, LDLR, CYP51A1, SQLE, and DHCR24.
[0017] FIG.3A. Workflow for zebrafish experiments with LPS versus controls.
[0018] FIG. 3B. Graph illustrating upregulation of genes for the LDL receptor (ldlra, ldlrb), dhcr7, dhcr24, msmo1, and cyp51 in LPS-treated zebrafish compared to controls.
[0019] FIG. 3C. Table representing differential expression analysis of RNA-seq data from three LPS treated zebrafish and three controls identified 12 lipid metabolism genes that were upregulated in LPS-treated zebrafish compared to controls.
[0020] FIG.3D. Table representing overlap of differentially expressed genes between derivation, validation, and zebrafish groups.
[0021] FIG.4A-B. Graphs illustrating effects of AY9944 and Triparanol on survival in Zebrafish sepsis model.
[0022] FIG.4C-D. Graphs illustrating effects of atorvastatin and torcetrapid on survival in Zebrafish sepsis model.
[0023] FIG.4E-F. Graphs illustrating effects of ezetimibe and U1866A on survival in Zebrafish sepsis model.
[0024] FIG.5. Graph illustrating survival in Zebrafish treated with a lethal dose of LPS and either no treatment, 7-DHC, 7-DHD, cholesterol, or desmosterol. Numbers in parenthesis indicates number of experiments.
[0025] FIG. 6: Graphs illustrating ΔΔCt for (A) Il1b and (B) Dhcr7 in mice injected intraperitoneally with PBS (control) or LPS. DETAILS DESCRIPTION I. Definitions
[0026] As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a polypeptide” may include two or more such molecules, and the like.
[0027] The use of "comprise," "comprises," "comprising,” "contain," "contains," "containing," "include," "includes," and "including" are not intended to be limiting. It is to be understood that both the foregoing general description and detailed description are exemplary and explanatory only and are not restrictive of the teachings. To the extent that any material incorporated by reference is inconsistent with the express content of this disclosure, the express content controls. Unless specifically noted, embodiments in the specification that recite “comprising” various components are also contemplated as “consisting of” or “consisting essentially of” the recited components. Embodiments in the specification that recite “consisting essentially of” various components are also contemplated as “consisting of.” “Consisting essentially of” means that additional component(s), composition(s), or method step(s) that do not materially change the basic and novel characteristics of the compositions and methods described herein may be included in those compositions or methods.
[0028] As used herein, the terms “about” and “approximately,” when used to modify an amount specified in a numeric value or range, indicates the numeric value as well as reasonable deviations from the value known to the skilled person in the art (e.g., not having any significant effect on the activity or stability of the composition). In some embodiments, the term “about” means within the typical ranges of tolerances in the art. In some embodiments, the term “about” means within 1 or 2 standard deviations from the mean. In some embodiments, the term “about” means ±10%. In some embodiments, the term “about” means ±5%. When the term “about” is present before a series of numbers or a range, it is understood that “about” can modify each of the numbers in the series or range. When the specification discloses a specific value for a parameter, the specification should be understood as alternatively disclosing the parameter at “about” that value.
[0029] All ranges are to be interpreted as encompassing the endpoints in the absence of express exclusions, such as “not including the endpoints”; thus, for example, “within 10-15” or “from 10 to 15” includes the values 10 and 15. Also, the use of “comprise,” “comprises,” “comprising,” “contain,” “contains,” “containing,” “include,” “includes,” and “including” are not intended to be limiting. It is to be understood that both the foregoing general description and detailed description are exemplary and explanatory only and are not restrictive of the teachings.
[0030] The term “subject,” “individual,” and “patient,” as used interchangeably herein, refer to a mammal, including but not limited to humans, non-human primates, rodents (e.g., rats, mice, and guinea pigs), rabbits, cows, pigs, horses, and other mammalian species. In some embodiments, the subject is a human.
[0031] The terms “treat,” “treatment,” and the like, mean the methods or steps taken to provide relief from, or amelioration or alleviation of the number, severity, adverse effect, and / or frequency of one or more symptoms or pathological consequences of a disease, disorder, or condition in a subject. Treatment can be prophylactic in terms of preventing or partially preventing a disease, or a symptom or condition of the disease. Preventing includes providing prophylaxis with respect to the occurrence or recurrence of a disease in a subject that may be predisposed to the disease but has not yet been diagnosed with the disease. Preventing also includes providing prophylaxis with respect to the occurrence or recurrence of a symptom or pathological consequence of a disease in a subject that may be predisposed symptom or pathological consequence of the disease but has not yet been diagnosed with the symptom or pathological consequence the disease. Treatment can also be prophylactic in terms of delaying onset of a disease, or a symptom or condition of the disease. Delaying development of a disease or symptom or pathological consequence of the disease indicates deferring, hindering, slowing, retarding, stabilizing, suppressing, and / or postponing development of the disease or symptom or pathological consequence of the disease. The delay can be of varying lengths of time, depending on the history of the disease and / or individual being treated. Treating can include inhibiting the disease, disorder, or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and / or condition. Treatment can also mean prolonging survival as compared to expected survival in the absence of treatment. Treatment can be therapeutic in terms of a partial or complete cure of a disease, condition, symptom, or adverse effect attributed to the disease, disorder, or condition. The term treatment can include: (a) preventing the disease from occurring in a subject who may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., mitigating or ameliorating the disease and / or its symptoms or conditions. Treating can refer to both therapeutic treatment alone, prophylactic treatment alone, or both therapeutic and prophylactic treatment. Those in need of treatment (subjects in need thereof) can include those previously diagnosed with a disease, disorder, or condition, or those identified as being at risk of developing a disease, disorder, or condition. Treating the disease, disorder, or condition can include ameliorating at least one symptom of the particular disease, disorder, or condition, even if the underlying pathophysiology is not affected.
[0032] The term “pharmaceutically acceptable excipient” refers to a non-active pharmaceutical ingredient that is biologically or pharmacologically compatible for use in humans or animals, such as but not limited to a buffer, carrier, or preservative.
[0033] An “effective amount” of an agent, or a pharmaceutical formulation containing the agent, in the context of administration, refers to an amount effective, at dosages / amounts and for periods of time necessary, to achieve a desired result, such as a therapeutic or prophylactic result.
[0034] A “therapeutically effective amount” of an agent, or a pharmaceutical formulation containing the agent, refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result, such as for treatment of a disease, condition, or disorder, and / or pharmacokinetic or pharmacodynamic effect of the treatment. The therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the subject, and the populations of cells administered.
[0035] A “dose,” “unit dose,” or “dosage” refers to physically discrete units suitable for use in a subject, each unit containing a predetermined quantity of active pharmaceutical ingredient and / or a pharmaceutical composition.
[0036] The term “administer” refers to a method of delivering agents, compounds, or compositions to the desired site of biological action. These methods include, but are not limited to, topical delivery, oral delivery, parenteral delivery, intravenous delivery, intradermal delivery, intramuscular delivery, intrathecal delivery, colonic delivery, rectal delivery, or intraperitoneal delivery. In some embodiments, the compositions described herein are administered intravenously. II. Overview
[0037] Sepsis occurs when a subject’s immune system has a dangerous reaction to an infection. Extensive inflammation throughout the body can lead to tissue damage, organ failure and even death. Sepsis happens when an existing infection triggers a chain reaction throughout the body. Infections that lead to sepsis most often start in the lung, urinary tract, skin, or gastrointestinal tract. Without timely treatment, sepsis can rapidly lead to tissue damage, organ failure, and death.
[0038] Described are compounds and methods for treating sepsis or systemic inflammatory response syndrome (SIRS). Treating sepsis or SIRS can include, but is not limited to: ameliorating one or more symptoms associated with sepsis or SIRS, reducing the severity of sepsis or SIRS, reducing the duration of sepsis or SIRS, and / or preventing the progression of sepsis or SIRS to chronic critical illness (CCI) or early death. In some embodiments, treating sepsis of SIRS comprises: reducing the risk of mortality associated with or caused by sepsis, increasing survival rate of a subject with or at risk of developing sepsis orSIRS, decreasing the morbidity and mortality caused by sepsis, preventing progression from sepsis to severe sepsis or septic shock, or preventing or decreasing the risk of multiple organ dysfunction syndrome associated with sepsis or SIRS.
[0039] In some embodiments, the methods comprise administering to a subject diagnosed with sepsis or SIRS, a compound that inhibits activity of Dhcr7 (Dhcr7 inhibitor) or inhibits expression of the DHCR7 gene (DHCR7 inhibitor). In some embodiments, the methods comprise administering to a subject suspected by having sepsis or SIRS, a compound that inhibits activity of Dhcr7 or inhibits expression of the DHCR7 gene. In some embodiments, the methods comprise administering to a subject at risk of developing sepsis or SIRS, a compound that inhibits activity of Dhcr7 or inhibits expression of the DHCR7 gene. In some embodiments, the methods comprise administering to a subject having one or more risk factors of developing sepsis or SIRS, a compound that inhibits activity of Dhcr7 or inhibits expression of the DHCR7 gene.
[0040] 7-dehydrocholesterol reductase (Dhcr7: Genbank: AAH00054.1, Uniport Q9UBM7, also termed 7-dehydrocholesterol Δ7 reductase) is an enzyme involved in the last step of cholesterol biosynthesis, converting 7-dehydrocholesterol (7DHC) into cholesterol. Dhcr7 is encoding by the DCHR7 gene (Gene ID: 1717, GenBank: LC201749.1, AF110060.1). III. Dhcr7 / DHCR7 inhibitors A. Dhcr7 inhibitors
[0041] In some embodiments, the Dhcr7 inhibitor comprises a small molecule known to inhibit Dhcr7 activity. Several small molecules are known to inhibit Dhcr7 activity.
[0042] In some embodiments, the Dhcr7 inhibitor comprises AY9944 [trans-1,4-bis(2- chloro-benzylaminomethyl) (CAS No. 366-93-8) (Wang H et al. “Targeting 7- dehydrocholesterol reductase against EV-A71 replication by upregulating interferon response” Antiviral Res 2023 Jan:209:105497.
[0043] In someatypical antipsychotic. Atypical antipsychotics, also known as second generation antipsychotics (SGAs) or serotonin– dopamine antagonists (SDAs), block receptors in the brain's dopamine pathways. Atypical antipsychotics are an antipsychotic drug typically used to treat psychiatric conditions. Atypical antipsychotics include, but are not limited to, ziprasidone, brexpiprazole, clozapine,cariprazine, perospirone, nefazodone, aripiprazole, and risperidone. In some embodiments, the Dhcr7 inhibitor comprises ziprasidone. In some embodiments, the Dhcr7 inhibitor comprises brexpiprazole.
[0044] (a) ziprasidone (CAS No.146939-27-7) (Ghersi D et al. “Identifying Molecular Fragments That Drive 7-Dehydrocholesterol Elevation” ACS Pharmacol Transl Sci. 2022 Jan 14; 5(1): 3–7)
[0045] (b) Mattos TC et al.“Dichlorophenyl piperazines, including a recently approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis” Toxicol Appl Pharmacol. 2018 Jun 15; 349: 21–28)
[0046] (c)al. “Antipsychotic drugs regulate hedgehog signaling by modulation of 7-dehydrocholesterol reductase levels” Mol Pharmacol.2010 Sep;78(3):486-96)
[0047] (d) cariprazine (CAS(Genaro-Mattos TC et al. “Maternal cariprazine exposure inhibits embryonic and postnatal brain cholesterol biosynthesis” Mol Psychiatry.2020 Nov;25(11):2685-2694.
[0048] (e) perospirone (CAS No. 150915-41-6) (Kim H-Y et al. “Inhibitors of 7- Dehydrocholesterol Reductase: Screening of a Collection of Pharmacologically Active Compounds in Neuro2a Cells” Chem Res Toxicol.2016 May 16;29(5):892-900)
[0049] (f) al.2016)
[0050] (g) Z et al. “Effect ofpsychotropic drug treatment on sterol metabolism” Schizophr Res. 2017 Sep:187:74- 81; Kim H-Y et al.2016)
[0051] (h)al.2016)
[0052] In somea 5-HT2Areceptor antagonist. 5-HT2A receptor antagonists include, but are not limited to, ketanserin. In some embodiments, the Dhcr7 inhibitor comprises ketanserin.
[0053] (a) ketanserin (CAS. No.74050-98-9)
[0054] In some embodiments, the Dhcr7 inhibitor comprises a dopamine receptor agonist. Dopamine receptor agonists include, but are not limited to, pergolide. In some embodiments, the Dhcr7 inhibitor comprises pergolide.
[0055] (a) pergolide (CAS. No. 66104-22-1) (Wages PA et al. “Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol” J Lipid Res.2018 Oct; 59(10): 1916–1926.)
[0056] In some a selective serotoninreuptake inhibitor (SSRI). SSRIs include, but are not limited to, vilazodone, fluoxetine, and trazodone. In some embodiments, the Dhcr7 inhibitor comprises vilazodone.
[0057] (a) vilazodone (CAS. No.163521-12-8) (Ghersi D et al.2022)
[0058] (b)
[0059] (c) trazodoneZ et al. 2017; Kim H-Y et al. 2016)
[0060] In some embodiments, the Dhcr7 inhibitor comprises a 5-HT1A receptor agonist (i.e., serotonin 5-HT1A receptor). 5-HT1Areceptor agonists include, but are not limited to: buspirone.
[0061] (a) buspirone (CAS. No.36505-84-7) (Kim H-Y et al.2016)
[0062] In some a β-2 adrenergic receptoragonist. β-2 adrenergic receptor agonist include, but are not limited to, indacaterol and metoprolol. In some embodiments, the Dhcr7 inhibitor comprises indacaterol.
[0063] (a) indacaterol (CAS. No.312753-06-3)
[0064] (b)et al. “Metoprolol Inhibits Developmental Brain Sterol Biosynthesis in Mice” Biomolecules.2022 Sep; 12(9): 1211)
[0065] AdditionalDhcr7 include, but are not limited to, tamoxifen, haloperidol, ifenprodil, cyclopamine, doxorubicin, BM 15.766, and GANT61. In some embodiments, the Dhcr7 inhibitor comprises tamoxifen.
[0066] (a) tamoxifen (CAS. No. 10540-29-1) (Xiao J et al. “Targeting 7- Dehydrocholesterol Reductase Integrates Cholesterol Metabolism and IRF3 Activation to Eliminate Infection” Immunity.2020 Jan 14;52(1):109-122.e6; Boland MR et al.2016)
[0067] (b) haloperidol (CAS. No. 52-86-8) (Korade Z et al. 2017; Kim H-Y et al. 2016))
[0068] (c) ifenprodil et al.2017)
[0069] (d) cyclopamineZou L et al. “Rapid suppression of 7-dehydrocholesterol reductase activity in keratinocytes by vitamin D” J Steroid Biochem Mol Biol.2015 Apr:148:64-71.)MR et al. “Investigation of 7- dehydrocholesterol reductase pathway to elucidate off-target prenatal effects of pharmaceuticals: a systematic review” Pharmacogenomics J.2016 Oct; 16(5): 411–429)
[0071] (f) BM 15.766 (CAS. No.86621-94-5) (Aufenanger J et al. “The effects of BM 15.766, an inhibitor of 7-dehydrocholesterol delta 7-reductase, on cholesterol biosynthesis in primary rat hepatocytes” Biochem Pharmacol.1986 Mar 15;35(6):911-6.
[0072] (g)B. DHCR7 inhibitors.
[0073] In some embodiments, the DHCR7 inhibitor comprises a nucleotide-based inhibitor of the DHCR7 gene. The DHCR7 inhibitor can be, but is not limited to, a RNAi agent (e.g., siRNA) targeting the DHCR7 mRNA or an antisense oligonucleotide targeting the DHCR7 mRNA.
[0074] A nucleic acid-based inhibitor comprises any polynucleotide that is not translated into protein but whose presence in the cell decreases expression of a target gene. In some embodiments, a nucleic acid-based inhibitor comprises a polynucleotide, including polynucleotides containing nucleotide analogs, containing a sequence whose presence or expression in a cell causes the degradation of or inhibits the function or translation of a specific cellular RNA, usually an mRNA, in a sequence-specific manner. Inhibition of RNA can thus effectively inhibit expression of a gene from which the RNA is transcribed. A nucleic acid- based inhibitor can comprise a RNA interference (RNAi) polynucleotide or an antisense oligonucleotide (ASO) that targets the DHCR7 gene. Contacting a cell with, or introducing into the cell, one or more RNAi polynucleotides or one or more antisense oligonucleotides can beused to inhibit expression of the DHCR7 gene in the cell. Inhibiting expression of the DHCR7 leads to decreased Dhcr7 activity in the cell.
[0075] An RNA interference (RNAi) polynucleotide is a molecule capable of inducing RNA interference through interaction with the RNA interference pathway machinery of mammalian cells to degrade or inhibit translation of messenger RNA (mRNA) transcripts of a transgene a sequence specific manner. RNAi polynucleotides may be selected from the group comprising: siRNA, microRNA, double-strand RNA (dsRNA), short hairpin RNA (shRNA), and expression cassettes encoding RNA capable of inducing RNA interference. siRNA comprises a double stranded structure typically containing 15-50 base pairs and preferably 21- 25 base pairs and having a nucleotide sequence identical (perfectly complementary) or nearly identical (partially complementary) to a sequence present in an expressed target gene or RNA within the cell. An siRNA may be composed of two annealed polynucleotides or a single polynucleotide that forms a hairpin structure. An siRNA molecule comprises a sense region and an antisense region. In some embodiments, a DHCR7 nucleic acid-based inhibitor comprises a double stranded ribonucleic acid (dsRNA) agent, such as an siRNA, for inhibiting expression of a DHCR7 gene in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides a sequence present in a DHCR7 mRNA and the antisense strand comprises at least 15 contiguous nucleotides from a sequence present in a complement of a DHCR7 mRNA.
[0076] An antisense oligonucleotide (ASOs) comprises an oligonucleotide having a nucleobase sequence that is complementary to a target nucleic acid or region or segment thereof. Antisense oligonucleotides include, but are not limited to: morpholinos, 2′-O-methyl polynucleotides, DNA, RNA, gapmers, and the like. Antisense nucleic acids act by hybridization of an antisense nucleotide sequence to its target nucleic acid. In certain embodiments, antisense activity is a decrease in the amount or expression of a target nucleic acid or protein encoded by such target nucleic acid compared to target nucleic acid levels or target protein levels in the absence of the antisense compound to the target. Antisense nucleic acid can inhibit gene expression by reducing the levels of target RNA in a cell or by inhibiting translation, splicing, or activity of an RNA in a cell. In some embodiments, a DHCR7 nucleic acid-based inhibitor comprises an ASO, wherein the ASO comprises at least 10 contiguous nucleotides from a complement of the nucleotide sequence of a DHCR7 mRNA. In some embodiments, the ASO comprises a gapmer.
[0077] siRNAs and ASOs can be designed using methods available in the art.IV. Methods of use
[0078] The described Dhcr7 inhibitors and DHCR7 inhibitors can be administered to a subject to treat or prevent sepsis or SIRS.
[0079] In some embodiments, systemic inflammatory response syndrome (SIRS) is defined by the presence of two or more of the following findings: (a) Body temperature <36° C (97° F) or >38° C (100° F) (hypothermia or fever). (b) Heart rate >90 beats per minute. (c) Respiratory rate >20 breaths per minute or, on blood gas, a Pa CO2less than 32 mm Hg (4.3 kPa) (tachypnea or hypocapnia due to hyperventilation). (c) White blood cell count <4,000 cells / mm3or >12,000 cells / mm3, or >10% immature (band) forms.
[0080] In some embodiments, the SIRS is related to a known of suspected infection or pathogen.
[0081] Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis can be defined as SIRS in response to a known of suspected infection (pathogen). Sepsis can also be defined as an increase of 2 or more in the SOFA (Sequential Organ Failure Assessment) or qSOFA (quick SOFA) score of a subject. Evidence of infection can be, but is not limited to, positive diagnostic test, (e.g., culture, stain, polymerase chain reaction (PCR), ELISA), a clinical syndrome pathognomonic for infection, white blood cells in a normally sterile fluid (e.g., urine or cerebrospinal fluid), evidence of a perforated viscus (free air on abdominal x-ray or CT scan; signs of acute peritonitis), abnormal chest x- ray (CXR) consistent with pneumonia (with focal opacification), petechiae, purpura, and purpura fulminans. Sepsis may be marked by the beginning of any organ dysfunction remote from a site of infection. For qSOFA, 1 point is given for each of altered mental status (Glasgow coma scale (GCS)score <15), respiratory rate ≥22, and systolic blood pressure ≤100 mm Hg. Table 1. SOFA score SOFA score1 2 3 4Cardiovascular Hypotension MAP* Dopamine ≤5 or Dopamine >5 or Dopamine >15 or 0.1
[0082] the pathogen is a bacteria. In some embodiments, the pathogen is a virus. In some embodiments, the pathogen is a fungus. In some embodiments, the pathogen in a parasite.
[0083] Severe sepsis is sepsis associated with organ dysfunction, hypoperfusion, or hypotension.
[0084] Septic shock is a subset of sepsis in which underlying circulatory and cellular / metabolic abnormalities are profound enough to substantially increase mortality. Septic shock is sepsis with hypotension or perfusion abnormalities despite provision of adequate fluid (volume) resuscitation. Perfusion abnormalities include lactic acidosis, oliguria, or an acute alteration in mental status. Septic shock may also be considered to be sepsis in which underlying circulatory and cellular–metabolic abnormalities are profound enough to substantially increase mortality (e.g., requiring vasopressor therapy to maintain a mean arterial blood pressure of >65 mmHg and an increased plasma lactate level of >2 mmol per liter.
[0085] Described is the use of one or more Dhcr7 inhibitors or DHCR7 inhibitors for use in the treatment of sepsis of SIRS.
[0086] In some embodiments, the Dhcr7 inhibitors or DHCR7 inhibitors are for use in treating, preventing and / or reducing the risk of sepsis or SIRS. The Dhcr7 inhibitor or DHCR7 inhibitor may be administered to a subject diagnosed with sepsis or SIRS, suspected of suffering from sepsis or SIRS, or at risk of developing sepsis or SIRS.
[0087] In some embodiments, the Dhcr7 inhibitors or DHCR7 inhibitors are for use in treating, preventing and / or reducing the risk of severe sepsis or septic shock. The Dhcr7 inhibitor or DHCR7 inhibitor may be administered to a subject diagnosed with severe sepsis or septic shock, suspected of suffering from severe sepsis or septic shock, or at risk of developing severe sepsis or septic shock.
[0088] In some embodiments, the Dhcr7 inhibitors or DHCR7 inhibitors are for use in treating, preventing and / or reducing the risk of developing one or more symptoms associated with sepsis, severe sepsis, septic shock, or SIRS. The Dhcr7 inhibitors or DHCR7 inhibitors may be administered to a subject diagnosed with sepsis, severe sepsis, septic shock, or SIRS, suspected of suffering from sepsis, severe sepsis, septic shock, or SIRS, or at risk of developing sepsis, severe sepsis, septic shock, or SIRS.
[0089] In some embodiments, the Dhcr7 inhibitors or DHCR7 inhibitors are for use in treating, preventing, or reducing the likelihood or risk of one or more complications associated with sepsis or SIRS. The one or more complications associated with sepsis or SIRS include, but are not limited, to, severe sepsis, severe SIRS, septic shock, and multi-organ failure. The Dhcr7 inhibitors or DHCR7 inhibitors may be administered to a subject diagnosed with sepsis or SIRS, suspected of suffering from sepsis or SIRS, or at risk of developing sepsis or SIRS.
[0090] In some embodiments, the Dhcr7 inhibitors or DHCR7 inhibitors are for use in reducing the risk or likelihood of multi-organ failure in a patient with or at risk of sepsis or SIRS. The Dhcr7 inhibitors or DHCR7 inhibitors may be administered to a subject diagnosed with sepsis or SIRS, suspected of suffering from sepsis or SIRS, or at risk of developing sepsis or SIRS.
[0091] In some embodiments, the Dhcr7 inhibitors or DHCR7 inhibitors are for use in reducing the risk or likelihood of severe sepsis in a patient with or at risk of sepsis or SIRS. The Dhcr7 inhibitors or DHCR7 inhibitors may be administered to a subject diagnosed with sepsis or SIRS, suspected of suffering from sepsis or SIRS, or at risk of developing sepsis or SIRS.
[0092] In some embodiments, the Dhcr7 inhibitors or DHCR7 inhibitors are for use in reducing the risk or likelihood of septic shock in a patient with or at risk of sepsis or SIRS. The Dhcr7 inhibitors or DHCR7 inhibitors may be administered to a subject diagnosed with sepsis or SIRS, suspected of suffering from sepsis or SIRS, or at risk of developing sepsis or SIRS.
[0093] In some embodiments, the Dhcr7 inhibitors or DHCR7 inhibitors are for use in preserving organ function, alleviating multi-organ failure and / or improving survival rate in a patient with or at risk of sepsis or SIRS. The Dhcr7 inhibitors or DHCR7 inhibitors may be administered to a subject diagnosed with sepsis, severe sepsis, septic shock, or SIRS, suspected of suffering from sepsis, severe sepsis, septic shock, or SIRS, or at risk of developing sepsis, severe sepsis, septic shock, or SIRS.
[0094] In some embodiments, the Dhcr7 inhibitors or DHCR7 inhibitors are for use in treating, preventing, or reducing the likelihood or risk of organ dysfunction, hypoperfusion,perfusion abnormalities and / or hypotension as a complication associated with sepsis or SIRS. The Dhcr7 inhibitors or DHCR7 inhibitors may be administered to a subject diagnosed with sepsis or SIRS, suspected of suffering from sepsis or SIRS, or at risk of developing sepsis or SIRS.
[0095] In some embodiments, the Dhcr7 inhibitors or DHCR7 inhibitors are for use in use in reducing mortality or morbidity associated with sepsis or SIRS. The Dhcr7 inhibitors or DHCR7 inhibitors may be administered to a subject diagnosed with sepsis or SIRS, suspected of suffering from sepsis or SIRS, or at risk of developing sepsis or SIRS.
[0096] In some embodiments, the Dhcr7 inhibitors or DHCR7 inhibitors are for use in reducing duration of hospitalization or intensive care associated with sepsis or SIRS. The Dhcr7 inhibitors or DHCR7 inhibitors may be administered to a subject diagnosed with sepsis or SIRS, suspected of suffering from sepsis or SIRS, or at risk of developing sepsis or SIRS.
[0097] In some embodiments, the Dhcr7 inhibitors or DHCR7 inhibitors are for use in reducing the need for dialysis, reducing the duration of the need of dialysis, reducing the need for ventilatory support, or reducing the duration of the need for ventilatory support for a subject with or at risk of sepsis or SIRS. The Dhcr7 inhibitors or DHCR7 inhibitors may be administered to a subject diagnosed with sepsis or SIRS, suspected of suffering from sepsis or SIRS, or at risk of developing sepsis or SIRS. V. Formulations
[0001] In some embodiments, the Dhcr7 inhibitor or DHCR7 inhibitor is formulated with one or more pharmaceutically acceptable excipients (including vehicles, carriers, diluents, and / or delivery polymers), thereby forming a pharmaceutical composition or medicament suitable for in vivo delivery to a subject, such as a human. The phrase “pharmaceutically acceptable” indicates that the substance or composition must be compatible chemically and / or toxicologically, with the other ingredients comprising a formulation, and / or the mammal being treated therewith.
[0002] A pharmaceutical composition or medicament includes a pharmacologically effective amount of a Dhcr7 inhibitor or a DHCR7 inhibitor and optionally one or more pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients (excipients) are substances other than the Active Pharmaceutical ingredient (API, therapeutic product) that are intentionally included in the drug delivery system. Excipients do not exert or are not intended to exert a therapeutic effect at the intended dosage. Excipients may act to a) aid in processing of the drug delivery system during manufacture, b) protect, support, or enhancestability, bioavailability or patient acceptability of the API, c) assist in product identification, and / or d) enhance any other attribute of the overall safety, effectiveness, of delivery of the API during storage or use. A pharmaceutically acceptable excipient may or may not be an inert substance.
[0003] Excipients include, but are not limited to: absorption enhancers, anti-adherents, anti-foaming agents, anti-oxidants, binders, buffering agents, carriers, coating agents, colors, delivery enhancers, delivery polymers, dextran, dextrose, diluents, disintegrants, emulsifiers, extenders, fillers, flavors, glidants, humectants, lubricants, oils, polymers, preservatives, saline, salts, solvents, sugars, suspending agents, sustained release matrices, sweeteners, thickening agents, tonicity agents, vehicles, water-repelling agents, and wetting agents.
[0004] The pharmaceutical compositions can contain other additional components commonly found in pharmaceutical compositions. Such additional components can include, but are not limited to: anti-pruritics, astringents, local anesthetics, or anti-inflammatory agents.
[0005] A carrier can be, but is not limited to, a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. A carrier may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. A carrier may also contain isotonic agents, such as sugars, polyalcohols, sodium chloride, and the like into the compositions.
[0006] Pharmaceutically acceptable refers to those properties and / or substances which are acceptable to the subject from a pharmacological / toxicological point of view. The phrase pharmaceutically acceptable refers to molecular entities, compositions, and properties that are physiologically tolerable and do not typically produce an allergic or other untoward or toxic reaction when administered to a subject. In some embodiments, a pharmaceutically acceptable compound is approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals and more particularly in humans.
[0007] In some embodiments, the pharmaceutical compositions further comprise one or more additional active ingredients. The additional active ingredient can be, but is not limited to, a second Dhcr7 inhibitor or DHCR7 inhibitor, an antibiotic, an antibody therapeutic, an immune modulator, or a pain reliever.
[0008] The pharmaceutical composition can be in a liquid formulation, a tablet, a coated tablet, a chewable tablet, a powder (e.g., a lyophilized powder), or a capsule. The pharmaceutical composition can be administered orally, by inhalation, (e.g., nasally) orparenterally. Parenteral administration can be, but is not limited to, intramuscular administration and intravenous administration. In some embodiments, the pharmaceutical composition is administered orally.
[0009] It is to be understood that the disclosures are not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. The skilled artisan will recognize many variants and adaptations of the aspects described herein. These variants and adaptations are intended to be included in the teachings of this disclosure and to be encompassed by the claims herein. EXAMPLES Example 1. Methods
[0098] Experimental Design. We analyzed transcriptomic data from four prospective studies of sepsis patients enrolled between November 2016 and July 2022 from the emergency department at UF Health Jacksonville. STROBE guidelines for observational studies were followed.
[0099] Patient Selection and Enrollment. UF Health Jacksonville emergency department patients meeting Sepsis-3 criteria were identified prospectively by trained research coordinators or providers within 24 hours of sepsis recognition (Singer M et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10). Patients from three observational studies and one ongoing clinical trial (LIPid Intensive Drug therapy for Sepsis Pilot, LIPIDS-P) were included in this analysis (Guirgis FW et al. A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes. Crit Care. 2021 Sep 17;25(1):341 and Guirgis FW et al. LIPid Intensive Drug therapy for Sepsis Pilot (LIPIDS- P): Phase I / II clinical trial protocol of lipid emulsion therapy for stabilizing cholesterol levels in sepsis and septic shock. BMJ Open.2019 Sep 18;9(9):e029348).
[0100] Data Collection. Prospectively collected data included demographics, place of residence, source of infection, and comorbidities. Clinical variables included triage and enrollment vital signs, SOFA score, timing of antibiotics, volume of intravenous fluids,vasopressor use and duration, and mechanical ventilation use and duration. Hospital length of stay (LOS), and ICU LOS were documented.
[0101] Clinical Outcomes and Adjudication. The primary outcome was one of three categories: 1) early death (within 2 weeks of sepsis onset), 2) Chronic Critical Illness (CCI) (total ICU stay > 14 days with organ dysfunction or total ICU ≤ 14 days but discharged to long- term acute care, another hospital, or hospice), or 3) rapid recovery (all others) (Mira JC et al. Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation- Immunosuppression and Catabolism Syndrome. Crit Care Med. 2017 Feb;45(2):253-262). Group adjudication by at least two clinician investigators was performed for the sepsis diagnosis, primary outcomes, primary and secondary source of infection, culture positivity and hospital disposition during sepsis adjudication meetings (Loftus TJ et al. Sepsis and Critical Illness Research Center investigators: protocols and standard operating procedures for a prospective cohort study of sepsis in critically ill surgical patients. BMJ Open. 2017;7(7):e015136). Discrepancies were resolved by the inclusion of a third clinician investigator. The social security death index was used to determine mortality for patients lost to follow up. Twenty-eight and ninety-day mortality were also recorded.
[0102] Blood Sampling, RNA-seq and RT-qPCR Analysis. Blood was drawn at the time of enrollment and within 24 hours of sepsis recognition and prior to any clinical trial drug administration. Clinical laboratory testing included cholesterol levels, and sequential organ failure assessment (SOFA) score laboratory measures including platelets, creatinine, and total bilirubin levels. Serum total cholesterol, HDL-C, and triglyceride levels were directly measured from serum samples. LDL-C was calculated using the Friedewald formula. RNA- seq was performed using the Illumina NextSeq 550 system (San Diego, CA). RT-qPCR was performed using Bio-Rad iQ SYBR Green Supermix (Cat# 1708882).
[0103] Zebrafish experiments. All wild-type fish were a hybrid line generated by crossing AB and TL fish acquired from the Zebrafish International Resource Center.
[0104] Data Analysis – Univariate Comparisons. Presenting vital signs, cholesterol levels, demographic information, clinical features, and clinical management data across the outcome groups and by mortality (28 and 90 day) were analyzed. We calculated medians and interquartile ranges for continuous variables and counts and proportions for categorical variables. To test for differences among outcome groups, we ran the Shapiro-Wilkes test of normality for each of the continuous variables. Only age was found to be normally distributed. Age was also found to have homogeneity of variances, per Bartlett’s test, thereby meeting the requirements to use an ANOVA procedure. For all other continuous variables, we used thenon-parametric Kruskal-Wallis procedure. We used Fisher’s Exact test to compare differences in categorical variables. We conducted a total of 28 tests comparing differences with the outcome group variable, then applied Bonferroni adjustment to proportionally correct our presented p-values. Analysis and calculations were completed in R (version 4.1.2; Vienna, Austria) using statistical tests from the Stats package.
[0105] Differential Expression Data Analysis. For data alignment, gene counts were obtained by aligning reads to the hg38 genome (GRCh38.p11) using STAR (v.2.7.9a) and featureCounts (v.2.0.3). We had two steps of analysis for the differential expression analysis: derivation and validation. We ensured a similar distribution of clinical outcomes across derivation and validation sets to detect differential expression patterns by outcome. To simplify the differential expression analysis, we combined early death and CCI patients into a “poor outcomes” group and compared them to rapid recovery patients who had more favorable outcomes. In a similar manner, we also performed a differential expression analysis by 90-day mortality. Twenty control samples were analyzed with the sepsis samples in the derivation set to compare gene expression patterns between the broader cohort of sepsis patients to healthy controls. The same differentially expressed genes detection protocol was used for both the derivation and validation steps of analysis. We included samples from two duplicate patients (both included in the validation set) enrolled in the study during two different sepsis episodes, over one year apart. Data were analyzed with and without these two additional patient encounters; their inclusion did not change the significant differentially expressed genes and so these encounters were included in the final results. In brief, the differential expression analysis was performed using DESeq2 in R (version 4.0.5; Vienna, Austria). Gene counts were modeled with a negative binomial generalized linear model and adjusted for batch effects. Wald tests were conducted for the pairwise comparisons. We identified genes with adjusted p-values (i.e., p-values after false discovery rate correction) less than 0.05 as the differentially expressed genes. We focused our analysis on a set of 47 prespecified lipid metabolism genes. Example 2. Clinical analyses.
[0106] The present analysis included 128 sepsis patient encounters and 20 healthy controls. The derivation cohort included 96 patients and controls (12 early death, 13 CCI, 51 rapid recovery, and 20 controls) and the validation cohort had 52 patients (six early death, eight CCI, and 38 rapid recovery). For sepsis patients, presenting vital signs were similar by outcomes. Distribution of comorbidities across the outcome groups were similar. Initial LDL- C levels were significantly lower for patients with early death or CCI compared to rapidrecovery patients. Total cholesterol, HDL-C, and triglyceride levels were not statistically significantly different between groups. CCI patients were significantly older (median 72 years) than early death (median 61.5 years) or rapid recovery (median 60 years). Median SOFA and APACHE II scores were significantly higher for CCI (11, 18, respectively) and early death (10, 21, respectively) compared to rapid recovery (5, 13, respectively) patients. There was a higher proportion of septic shock patients in the early death and CCI groups compared to rapid recovery. The most common source of infection was pulmonary (27%), urinary tract (25%), and multiple sources of infection (17%). There were no significant differences in patient management characteristics.
[0107] For the differential expression analysis, the derivation cohort had 96 single-end sequencing samples, including 12 early death, 13 CCI, 51 rapid recovery, and 20 healthy control patient samples. The validation cohort had 58 paired-end sequencing samples of sepsis patients, including eight early death, 12 CCI, and 38 rapid recovery. Patients included in the derivation cohort had a similar age, gender, and race distribution compared to patients in the validation set. With the exception of triglycerides, presenting cholesterol and lipid levels were similar between derivation and validation cohorts. They also had similar Apache II and SOFA scores, proportions of shock patients, and clinical management.
[0108] FIG. 1 depicts the workflow for RNA-seq data analysis (FIG. 1A) and significantly differentially expressed genes for the derivation and validation cohorts (FIG.1B) and by 90-day mortality (FIG. 1C). In the derivation cohort, 458 of 39,372 genes were differentially expressed by patient outcome, including six of the 47 lipid metabolism genes. In the validation cohort, 501 of 36,585 genes were identified as differentially expressed genes, including 2 lipid metabolism genes. Of the 47 lipid metabolism genes, there were 6 significant genes identified in the derivation cohort (CYP51A1, DHCR24, DHCR7, MSMO1, SQLE, and LDLR), and 2 genes identified in the validation cohort (DHCR7 and ALOX5). All of these genes were upregulated in early death / CCI patients when compared to rapid recovery patients. FIG. 2 displays heatmaps of differentially expressed genes for derivation and validation cohorts. Five of the significant derivation cohort genes encoded enzymes that catalyze critical steps in the biosynthesis of cholesterol (CYP51A1, DHCR24, DHCR7, MSMO1, SQLE). CYP51A1 is critical for cholesterol synthesis, steroid synthesis, and drug metabolism. LDLR encodes the LDL receptor which endocytoses LDL-C from circulation. Both significant genes from the validation cohort were upregulated in CCI / early death patients compared to rapid recovery. ALOX5 is the critical enzyme for the generation of all leukotrienes, potent mediators ofinflammation. The only gene identified to be significantly upregulated in both cohorts was DHCR7.
[0109] We performed a differential expression analysis by 90-day mortality. None of the lipid metabolism genes of interest were detected in the derivation cohort. However, DHCR7 and PLTP were detected and upregulated in the validation cohort (FIG. 1). PLTP encodes a protein that is important for cholesterol and LPS clearance, and transfers phospholipids from triglyceride-rich lipoproteins. It also helps to regulate HDL size and is involved in cholesterol and LPS clearance (Barker G et al 2021).
[0110] We next examined gene expression in sepsis patients and healthy controls by RT-qPCR. Based on availability of total RNA, we picked 10 CCI, 12 early death, 12 rapid recovery patients and 11 healthy controls for RT-qPCR. Five of the six genes (LDLR, DHCR24, DHCR7, MSMO1, SQLE) identified in the RNA-seq analysis were significantly upregulated in comparison to controls, while CYP51A1 was not. Example 3. Zebrafish model.
[0111] Results were corroborated in a zebrafish model of endotoxemia, which further allowed the functional testing of relevant genes. Zebrafish were selected as they are vertebrates that share many anatomic and physiologic similarities with humans, most aspects of the immune response, and nearly all elements of lipid and lipoprotein metabolism. Workflow for zebrafish experiments with LPS versus controls is depicted in FIG. 3A. RT-qPCR of cholesterol related genes showed upregulation of genes for the LDL receptor (ldlra, ldlrb), dhcr7, dhcr24, msmo1, and cyp51 in LPS-treated zebrafish compared to controls (FIG. 3B). Differential expression analysis of RNA-seq data from three LPS treated zebrafish and three controls identified 12 lipid metabolism genes that were upregulated in LPS-treated zebrafish compared to controls (FIG.3C). Notably, 6 of the genes (dhcr7, dhcr24, sqlea, cyp51, msmo1, and ldlra) were also upregulated in CCI / early death sepsis patients in the derivation cohort, as was dhcr7 in the validation cohort. Overlap of significantly differentially expressed genes between derivation, validation, and zebrafish groups is depicted in FIG.3D.
[0112] We tested several cholesterol metabolism drugs in our zebrafish model including AY9944 (Dhcr7 inhibitor), triparanol (Dhcr24 inhibitor), atorvastatin (HMG-CoA reductase inhibitor), torcetrapib (CETP inhibitor), and ezetimibe (cholesterol absorption inhibitor). Results of all zebrafish drug experiments are displayed in FIG. 4 (A-F). Varying concentrations of each drug were administered at 3 days post fertilization (dpf) with or without a dose of LPS that caused complete lethality by 4 dpf. For AY9944 (Dhcr7 inhibitor), 10-20µM of AY9944 alone showed no effects on survival. When administered with LPS, the 10 µM dose led to partial protection against mortality, while 20 µM resulted in 100% survival up to 6 dpf. None of the other drugs tested protected against LPS death.
[0113] Also tested were administration of 7-dehydrocholesterol (7-DHC) and 7- dehydrodesmosterol (7-DHD). Zebrafish were administered a lethal dose of LPS and either no cotreatment, 7-DHC, 7-DHD, cholesterol, or desmosterol. 7-DHC or 7-DHD are cholesterol precursors generated whin DHCR7 activity is inhibited. Cholesterol and Desmosterol conferred partial protection from LPS toxicity, but caused morphological defects in surviving fish. 7-DHC and 7-DHD protected the zebrafish from a lethal dose of LPS and did not cause morphological defects (FIG.5). Example 4. Mouse model
[0114] Mice were administered LPS via intraperitoneal injection. qPCR was then used to determiner Il1b and DHCR7 expression. As shown in FIG.6, LPS administration resulted in an increase in the expression of both Il1b and Dhcr7. Upregulation of DHCR7 in humans in sepsis samples and in mice and zebrafish treated with LPS indicate DHCR7 pathway is conserved in mammals. Example 5. Role of inhibiting DHCR7 in treating sepsis.
[0115] In this study, we performed an unbiased differential expression analysis of leukocyte gene expression RNA-seq data from diverse, prospective cohorts of sepsis patients. We further investigated 47 lipid metabolism genes to delineate lipid metabolic changes in sepsis patients by outcome and identified DHCR7 to be significantly and consistently upregulated for patients with CCI / early death and in the 90-day mortality group, when compared to healthy controls and rapid recovery patients. DHCR7 encodes an enzyme that removes the double bond in the B ring of sterols and catalyzes the conversion of 7-dehydroxycholesterol (7DHC) to cholesterol. 7DHC is also a precursor to vitamin D, catalyzed by DHCR7. In a parallel set of RNA-seq studies conducted in a zebrafish sepsis model, we observed that dhcr7 was significantly upregulated in samples from zebrafish that received lethal doses of LPS when compared to controls. Moreover, pharmacologic blockade of Dhcr7 resulted in complete rescue from death. These results are consistent with Dhcr7 having a mechanistic link to endotoxic death in a zebrafish sepsis model.
[0116] DHCR7 is a critical gene involved in cholesterol biosynthesis, immune regulation, and metabolism. Patients with loss of function mutations in DHCR7 develop Smith-Lemli-Optiz syndrome, which results in branchial and cardiac defects, electrolyte abnormalities (hypocalcemia, hyponatremia, hyperkalemia) and extremely low cholesterol levels (<38.7 mg / dL) associated with necrotizing enterocolitis, recurrent infections, sepsis-like episodes, and death in several patients. In a recent study, the genetic association of variants in the DHCR7 gene (and other genes for vitamin D metabolism) with subsequent bacterial pneumonia was studied (Çolak Y et al. Low vitamin D and risk of bacterial pneumonias: Mendelian randomisation studies in two population-based cohorts. Thorax. 2021 May;76(5):468-478. Epub 2020 Oct 27). They found that genetic variants of CYP2R1 but not DHCR7, GEMIN2 or HAL were associated with increased risk of bacterial pneumonias.
[0117] Recently, the potential mechanistic role of DHCR7 in combatting systemic infections has been studied. Xiao and colleagues showed that DHCR7 inhibition or genetic ablation enhanced both in vivo and in vitro macrophage-mediated anti-viral function (Xiao J et al. Targeting 7-Dehydrocholesterol Reductase Integrates Cholesterol Metabolism and IRF3 Activation to Eliminate Infection. Immunity. 2020 Jan 14;52(1):109-122.e6. Epub 2019 Dec 24). They demonstrated that two DHCR7 inhibitors (AY9944 and tamoxifen) led to increased clearance of vesicular stomatitis virus (VSV) and Zika virus. AY9944 administered to virus- infected (VSV or murine cytomegalovirus) macrophages led to enhanced Ifnb production in control macrophages but failed to enhance Ifnb production in DHCR7-deficient macrophages. The treatment of macrophages with tamoxifen also resulted in enhanced Ifnb expression upon treatment with a TLR3 agonist or VSV. Tamoxifen has also been shown to enhance neutrophil- mediated phagocytosis and extracellular trap formation to clear bacteria and has been proposed as a potential agent for combatting multi-drug resistant gram-negative infections.
[0118] We discovered a number of genes involved in the cholesterol synthesis pathway to be upregulated in sepsis patients when compared to healthy controls. While this could be a general response to reduced LDL-C and HDL-C levels in sepsis, the expression of some of these genes discriminated sepsis patients with CCI / early death outcomes from those in the rapid recovery and control groups, suggesting potential bedside prognostic utility. Our mortality analysis also revealed some additional insights. The upregulation of DHCR7 and PLTP for 90- day mortality emphasizes the important role that DHCR7 (and PLTP) may play in death from sepsis. In addition to regulating HDL size and facilitating cholesterol and LPS clearance, PLTP plays a role in the immunomodulatory action of HDL and is a factor in maintaining plasma sphingosine-1-phosphate levels (S1P). S1P, which is primarily carried on HDL in association with apolipoprotein M, has antiapoptotic and chemotactic effects and levels decline in sepsis. Declining S1P levels have a strong inverse relationship with organ failure (Winkler MS, et al.Loss of sphingosine 1-phosphate (S1P) in septic shock is predominantly caused by decreased levels of highdensity lipoproteins (HDL). J Intensive Care 2019; 7:23).
[0119] In conclusion, this study identified DHCR7 upregulation as influencing poor outcomes after sepsis (CCI / early death) in humans. Our robust findings in human sepsis, confirmed in a validation cohort as well as with RT-qPCR analysis, were then recapitulated in a zebrafish LPS sepsis model with similar differential expression of DHCR7 in LPS-treated zebrafish. Blockade of Dhcr7 led to complete rescue of LPS-treated zebrafish from LPS death, a model of mammalian sepsis.
Claims
Claims:
1. A method for treating or preventing sepsis or systemic inflammatory response syndrome (SIRS) in a subject, comprising administering to the subject an inhibitor of 7- dehydrocholesterol reductase (Dhcr7).
2. The method of claim 1, wherein the inhibitor comprises a chemical inhibitor selected from the group consisting of: an atypical antipsychotic, a 5-HT2A receptor antagonist, a dopamine receptor agonist, a selective serotonin reuptake inhibitor (SSRI), a 5- HT1A receptor agonist, and a β-2 adrenergic receptor agonist.
3. The method of claim 2, wherein the atypical antipsychotic is selected from the group consisting of: cariprazine, perospirone, nefazodone, aripiprazole, risperidone, ziprasidone, and brexpiprazole.
4. The method of claim 2, wherein the 5-HT2Areceptor antagonist is ketanserin.
5. The method of claim 2, wherein the dopamine receptor agonist is pergolide.
6. The method of claim 2, wherein the SSRI is selected from the group consisting of: vilazodone, fluoxetine, and trazodone.
7. The method of claim 2, wherein the 5-HT1Areceptor agonist is buspirone.
8. The method of claim 2, wherein the β-2 adrenergic receptor agonist is selected from the group consisting of: indacaterol, metoprolol.
9. The method of claim 1, wherein the inhibitor is selected from the group consisting of: AY9944, ziprasidone, ketanserin, pergolide, vilazodone, brexpiprazole, indacaterol, and tamoxifen.
10. The method of any one of claims 1-9, wherein the inhibitor is administered orally, sublingually, buccally, intravenously, intramuscularly, intrathecally, subcutaneously, cutaneously, transdermally, nasally, or by inhalation.
11. The method of claim 1, wherein the inhibitor comprises a nucleotide-based inhibitor or DHCR7.
12. The method of claim 11, wherein the nucleotide-based inhibitor comprises a DHCR7 RNA interference (RNAi) polynucleotide or a DHCR7 antisense oligonucleotide (ASO).
13. The method of claim 12, wherein the nucleotide-based inhibitor is delivered via a lipid nanoparticle or a viral vector.
14. The method of claim 13, wherein the viral vector is an adeno-associated virus (AAV) vector or lentivirus vector.
15. The method of any one of claims 1-14, wherein the subject is a human.
16. The method of any one of claims 1-15, wherein treating a subject suffering from sepsis or SIRS comprises ameliorating one or more symptoms associated with sepsis or SIRS, reducing the severity of sepsis or SIRS, reducing the duration of sepsis or SIRS, and / or preventing the progression of sepsis or SIRS to chronic critical illness (CCI) or early death.
17. The method of any one of claims 1-16, wherein treating or preventing sepsis or SIRS comprises: (a) treating, preventing, and / or reducing the risk of developing one or more symptoms associated with sepsis, severe sepsis, septic shock, or SIRS; (b) treating, preventing, or reducing the risk of developing of one or more complications associated with sepsis or SIRS; (c) reducing the risk of mortality associated with or caused by sepsis or SIRS; (d) increasing survival rate of a subject with or at risk of developing sepsis or SIRS; (e) preventing or reducing the risk of progression from sepsis to sever sepsis or septic shock (f) treating, preventing or reducing the risk of developing sever sepsis or septic shock; (g) treating, preventing, or decreasing the risk of developing multiple organ dysfunction syndrome associated with sepsis or SIRS; or (h) treating, preventing, or reducing the likelihood or risk of developing organ dysfunction, hypoperfusion, perfusion abnormalities and / or hypotension associated with sepsis or SIRS.
18. The method of any one of claims 1-17, wherein the sepsis comprises severe sepsis or septic shock.
19. The method of any one of claims 1-18, wherein the sepsis or SIRS is related to a known or suspected infection.
20. A Dhcr7 inhibitor or DHCR7 inhibitor for use in the treatment or prevention of sepsis, SIRS, severe sepsis, or septic shock.
